ScripTariffs are a key topic these days at biopharma events and things were no different at Cipla’s annual general meeting (AGM), especially amid US President Donald Trump’s continued threat and changing t
ScripFrontline Indian firms appear keen to accelerate product in-licensing deals with foreign companies and these efforts have now evolved from a “supplementary tactic” to a cornerstone of their strategy,
Pink SheetThe European Medicines Agency has begun reviewing a new batch of products for potential pan-EU marketing approval, including LIB Therapeutics’ lerodalcibep for treating primary hypercholesterolemia or
Generics BulletinFrontline Indian company Cipla said that an early assessment of US President Donald Trump’s executive order (EO) aimed at reducing prescription drug prices in line with those paid by similar nations